HIV-1 and HCV viral load cost models for bDNA: 440 Molecular System versus real-time PCR AmpliPrep^®/TaqMan^® test

References

• Hammer SM, Saag MS, Schechter M et al. Treatment for Adult HIV infection. Recommendations of the International AIDS Society – USA Panel. J. Amer. Med. Assoc.296(7), 827–843 (2006).
   PubMed Web of Science ®Google Scholar
• Department of Veterans Affairs Hepatitis C Resource Center; Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am. J. Gastroenterol.101(10), 2360–2378 (2006).
   PubMed Web of Science ®Google Scholar
• Terrault NA, Pawlotsky JM, McHutchison J et al. Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J. Vir. Hep.12(5), 465–472 (2005).
   PubMedGoogle Scholar
• Calmy A, Ford N, Hirschel B et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin. Infect. Dis.44(1), 128–134 (2007).
   PubMed Web of Science ®Google Scholar
• Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin. Lab.53(3–4), 135–148 (2007).
   PubMed Web of Science ®Google Scholar
• de Lamballerie X, Colson P. The battle against infectious diseases in developing countries: the inseparable twins of diagnosis and therapy. Clin. Chem.52(7), 1217 (2006).
   PubMedGoogle Scholar
• Stevens G, Rekhviashvili N, Scott LE, Gonin R, Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J. Clin. Microbiol.43(2), 857–861 (2005).
   PubMed Web of Science ®Google Scholar
• Steegen K, Demecheleer E, De Cabooter N et al. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance. J. Virol. Methods133(2), 137–145 (2006).
   PubMed Web of Science ®Google Scholar
• Drosten C, Panning M, Drexler JF et al. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5´ long terminal repeat domain clinical chemistry. Clin. Chem.52(7), 1258–1266 (2006).
   PubMed Web of Science ®Google Scholar
• Rouet F, Ekouevi DK, Chaix ML et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol.43(6), 2709–2717 (2005).
   PubMed Web of Science ®Google Scholar
• Elbeik T, Markowitz N, Nassos P et al. Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow. J. Clin. Microbiol.42(7), 3120–3127 (2004).
   PubMed Web of Science ®Google Scholar
• Elbeik T, Delassandro R, Chen YMA, Soutchkov SV, Loftus, RA, Beringer S. Global cost modeling analysis of HIV-1 and HCV viral load assays. Exp. Rev. Pharmacoeconomics Outcomes Res.3(4), 383–407 (2003).
   PubMedGoogle Scholar
• Schrijver I, Baron E J. Labor and cost requirements of two commercial assays for qualitative molecular detection of hepatitis C virus. J. Clin. Microbiol.40(9), 3476–3477 (2002).
   PubMedGoogle Scholar
• Elbeik T, Charlebois E, Nassos P et al. Quantitative and cost comparison of ultrasensitive HIV-1 RNA viral load assays: Bayer bDNA Quantiplex versions 3.0 and 2.0 and Roche PCR Amplicor MONITOR version 1.5. J. Clin. Microbiol.38(3), 1113–1120 (2000).
   PubMed Web of Science ®Google Scholar
• Tsongalis GJ. Branched DNA technology and molecular diagnostics. Am. J. Clin. Pathol.126(3), 448–453 (2006).
   PubMedGoogle Scholar
• Elbeik T, Loftus RA, Beringer S. Health care industries’ perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Rev. Mol. Diagn.2(3), 275–285 (2002).
   PubMedGoogle Scholar
• Schumacher W, Frick E, Kauselmann M, Maier-Hoyle V, van der Vliet R, Babiel R. Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol.38(4), 304–312 (2007).
   PubMed Web of Science ®Google Scholar
• Gleaves CA, Welle J, Campbell M et al. Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J. Clin. Virol.25(2), 205–216 (2002).
   PubMed Web of Science ®Google Scholar
• Elbeik T, Surtihadi J, Destree M et al. Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J. Clin. Microbiol.42(2), 563–569 (2004).
   PubMed Web of Science ®Google Scholar
• Sizmann D, Boeck C, Boelter J et al. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol.38(4), 326–333 (2007).
   PubMed Web of Science ®Google Scholar
• Wittek M, Stürmer M, Doerr HW, Berger A. Molecular assays for monitoring HIV infection and antiretroviral therapy. Expert Rev. Mol. Diagn.7(3), 237–246 (2007).
   PubMed Web of Science ®Google Scholar
• Fiscus SA, Cheng B, Crowe SM et al. Forum for collaborative HIV research alternative viral load assay working group. HIV-1 viral load assays for resource-limited settings. PLoS Med.3(10), E417 (2006).
   PubMed Web of Science ®Google Scholar
• Preiser W, Drexler JF, Drosten C. HIV-1 viral load assays for resource-limited settings: clades matter. PLoS Med.3(12), E538 (2006).
   Google Scholar
• Rouet F, Chaix ML, Nerrienet E et al. Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. J. Acquir. Immune Defic. Syndr.45(4), 380–388. (2007)
   PubMed Web of Science ®Google Scholar
• Steegen K, Luchters S, De Cabooter N et al. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings. J. Virol. Methods (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Berger A, Scherzed L, Sturmer M, Preiser W, Doerr HW, Rabenau HF. Comparative evaluation of the Cobas Amplicor HIV-1 MONITOR ultrasensitive test, the new Cobas AmpliPrep/Cobas Amplicor HIV-1 MONITOR ultrasensitive test and the VERSANT HIV RNA 3.0 assays for quantitation of HIV-1 RNA in plasma samples. J. Clin. Virol.33(1), 43–51 (2005).
   PubMedGoogle Scholar
• Martin DJ, Sim J. Requirements for scaling up HIV treatment. Southern African HIV Clinicians Society and Toga Labs, Johannesburg. Session 3 Symposium: Scaling Up HIV in the Developing World. Presented at: The 12th Conference on Retroviruses and Opportunistic Infections. Hynes Convention Center, Boston, MA, USA 22–25 February 2005 (Abstract 3).
   Google Scholar
• James JS. Clinton Foundation negotiates $140/Year HIV treatment, but U.S. won’t buy. AIDS Treat. News399, 2–4 (2004).
   Google Scholar
• Brinkman K. The price of HIV treatment. Neth. J. Med.61(12), 391–392 (2003).
   PubMedGoogle Scholar
• Sharma DC. ARV prices nosedive after Clinton brokering. Lancet362(9394), 1467 (2003).
   PubMedGoogle Scholar
• Elbeik T, Nassos P, Kipnis P, Haller B, Ng VL. Evaluation of the VACUTAINER PPT Plasma Preparation Tube for use with the Bayer VERSANT assay for quantification of human immunodeficiency virus type 1 RNA. J. Clin. Microbiol.43(8), 3769–3771 (2005).
   PubMedGoogle Scholar
• Holodniy M, Rainen L, Herman S, Yen-Lieberman B. Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment. J. Clin. Microbiol.38(1), 323–326 (2000).
   PubMed Web of Science ®Google Scholar